The field of adoptive cell therapy for solid malignancies have made groundbreaking strides using tumor-infiltrating lymphocytes (TILs). Despite the progress, there are still hurdles to overcome in TIL manufacturing. The journey to success lies in refining manufacturing protocols for a brighter clinical outlook.
Join this webinar and discover innovative cell manufacturing solutions. Learn how to generate tumor-reactive T cells (TRTs) for TIL therapy, all within a standardized and seamlessly automated framework.
Attend this webinar to learn about: